

2018 MID-YEAR ACTIVITY REPORT

Consolidated turnover for the first semester increases by 29% to 25.1 M€
mainly driven by the acquisition of Eurobio

On a like-for-like basis, turnover grew by 2%

Paris, July 23, 2018 – 5.45 pm

Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty *in vitro* medical diagnostics and life sciences, today presents its consolidated half-year turnover for the period ending June 30, 2018.

Strong growth of 29% to € 25.1 million

Driven by the acquisition of Eurobio that was completed on March 30, 2017, the Group's turnover increased by +29% to € 25.1 million in the first half of 2018, the Group's new scope of consolidation including sales made by Eurobio since January 1st, 2018.

On a like-for-like basis, i.e. including Eurobio's sales during the first quarter of 2017, mid-year turnover increased by 2%. This growth rate is similar to the turnover growth rate at constant scope between the first half of 2016 and that of 2017.

in € million	S1 2018	S1 2017 ⁽¹⁾	Var.	S1 2017 like-for-like ⁽²⁾	Var.
Total	25.1	19.6	+29%	24.6	+2%

Unaudited

Breakdown of turnover by activity will be presented with mid-year results

(1) Turnover including sales made by Eurobio since its acquisition on March 30, 2017

(2) Turnover including sales made by Eurobio since January 1st, 2017

In line with the Group's strategy, the activity during the first half of 2018 is driven by the Disease Diagnostics division (diagnostic tests and tests for monitoring the effectiveness of treatments for biology laboratories), whose sales are growing quite rapidly and offset those in the Transplantation division, which were down this semester in a mature market. Regarding the Research Products division, sales remained stable at about 10% of the Group's turnover.

Strong increase in profitability expected in 2018

"Beyond the synergies associated with the merger between Eurobio and Ingen, our sales are growing, driven by our Disease Diagnostics division and in particular by molecular biology. This good performance allows us to continue to anticipate a slight growth on a like-for-like basis over the year, to also better balance our product portfolio, and to focus on our objective of significantly increasing the Group's EBITDA for 2018," declares Jean-Michel Carle, Chairman of the Management Board of Eurobio Scientific.

Upcoming financial meetings

First Half 2018 earnings: October 9, 2018

About Eurobio Scientific

Eurobio Scientific (ex Diaxonhit) is a key player in the field of specialty *in vitro* diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 120 employees and two production units based in the Paris region and in the United States.

For more information, please visit: www.eurobio-scientific.fr

The company is publicly listed on the Euronext Growth market in Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices.
Symbol : ALERS - ISIN Code: FR0013240934 - Reuters : ALERS.PA - Bloomberg : ALERS:FP

Contacts

Eurobio Scientific Group

Denis Fortier, General Manager
Hervé Duchesne de Lamotte, General Manager
Tel. +33 1 69 79 64 80

Calyptus

Sophie Levesque / Mathieu Calleux
Investor Relations
Tel. +33 1 53 65 68 68
eurobio-scientific@calyptus.net